Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant trametinib and pembrolizumab before surgery for malignant glioma
ACTRN12625001269426Phase 2Not yet recruiting
- Sponsor
- Sir Charles Gairdner Hospital
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib and pembrolizumab in glioblastoma (GBM) and malignant glioma (2 arms), sponsored by Sir Charles Gairdner Hospital. Primary endpoints: Safety and tolerability of treatment regimen, Histological evidence of blood vessel normalization and 1 more. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
trametinibpembrolizumab
03
Conditions
glioblastoma (GBM)malignant glioma
Beyond the preview
Go deeper on ACTRN12625001269426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625001269426.